Breaking news

America’s Race For Humanoid Robots: Can It Catch Up with China?

U.S. tech giants are betting big on humanoid robots, but analysts warn they’re already trailing China. With Nvidia’s Jensen Huang and Tesla’s Elon Musk fueling investor enthusiasm, the competition is heating up. Yet, China’s rapid progress mirrors its dominance in electric vehicles, positioning it ahead in this new frontier.

The Robotics Revolution

Humanoid robots—AI-driven machines designed to mimic human movement—are set to transform industries from manufacturing to customer service. The U.S. sees them as crucial to future economic growth, but analysts caution that China’s aggressive industrial policies and supply chain advantages give it a head start.

Nvidia’s Huang recently unveiled new tech for humanoid robotics, while Musk’s Tesla aims to produce 5,000 Optimus robots in 2024. That puts it ahead of U.S. rivals like Apptronik and Boston Dynamics, but not China’s Agibot, which has matched Tesla’s production target. Meanwhile, Unitree Robotics has already sold humanoid models directly to consumers.

Price & Scale: China’s Edge

Morgan Stanley estimates humanoid robot production costs range from $10,000 to $300,000. But China’s scale is driving prices down. Unitree’s G1 starts at $16,000, while Tesla’s Optimus Gen2 is projected at $20,000—if Tesla can optimize costs using Chinese components.

China isn’t just ahead on pricing. Over the past five years, it has filed 5,688 humanoid robot patents—compared to just 1,483 from the U.S. EV giants like BYD and Geely have already deployed Unitree’s robots in factories, while Beijing actively supports large-scale production.

The U.S. Challenge

A recent SemiAnalysis report warns that China’s humanoid robots are entirely independent of U.S. components, posing an “existential threat” to American industry. To compete, U.S. firms must strengthen domestic manufacturing and diversify supply chains.

Bank of America predicts humanoid robot adoption will soar, reaching 1 million annual sales by 2030 and 3 billion in operation by 2060. But for now, China leads. If the U.S. wants a stake in the future of robotics, time is running out.

EU Records €220.5 Billion Pharmaceutical Trade Surplus In 2025

The European Union secured a historic trade surplus in medicinal and pharmaceutical products in 2025, according to a report from Eurostat. Export figures reached €366.2 billion while imports totaled €145.7 billion, leading to a surplus of €220.5 billion.

Robust Growth In Exports And Imports

Exports increased by 16.0% from €315.7 billion in 2024. Imports rose by 21.0% from €120.4 billion over the same period. The data show continued expansion in trade volumes across the sector.

Leading National Performances

Ireland recorded the highest exports to non-EU countries at €93.8 billion. Germany and Belgium followed with €67.9 billion and €38.5 billion, respectively. Italy led imports at €27.5 billion, with Belgium and Germany also recording significant volumes.

Global Trade Partnerships

The United States was the largest destination for EU exports, accounting for 43.8% or €160.6 billion. Switzerland followed with 16.3% (€59.7 billion), while the United Kingdom accounted for 5.6% (€20.6 billion). On the import side, the United States supplied 41.2% of total imports (€60.1 billion), followed by Switzerland at 28.4% (€41.4 billion) and China at 9.0% (€13.1 billion).

Aretilaw firm
The Future Forbes Realty Global Properties
eCredo
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter